Evad Tseuw

I am so sick of the CP team....you really have destroyed the company in so many ways along with the Hell's Kitchen tool at the top.

 

Puddie, did you read KYs article? Did you understand it?? Or, did SB have to tell you how to interpret it? KY is never going to be the CEO of GILD! He doesnt have the temperment or the intelligence. He only has false bravado and buffoons like you and SB to take with him to do his bidding.

 

Happy Halloween-

Team-

Welcome to 2010!

First, let me take this opportunity to wish a very Happy New Year to all of
you and hope you thoroughly enjoyed the time off with friends and family as
I did.

At the upcoming National Meeting in San Diego later this month we will come
together to calibrate our individual and collective objectives, priorities
and tactical approaches that will define our success in 2010. We will also
take the opportunity to celebrate our successes in 2009 as President¹s Club
Winners, Director¹s Awards Winners, Quarterly Award Winners and Sprint to
the Finish Contest Winners will be recognized.

As you are all aware, this year there is a special incentive compensation
opportunity to strive for in the form of an unprecedented 4 quarter long
sales contest was rolled out last Fall providing each of you the opportunity
to add a whopping 50% payout on top of your standard incentive compensation
payout if you are able to achieve a cumulative IC attainment of 95% or
greater over the 4 quarter contest period (Q409 and Q1, Q2 and Q3
2010)Šsimply put, a quick start out of the gates over the next few weeks and
on the heels of the upcoming National Meeting is a great chance to
capitalize on the Q1 incentive program and position yourself well for the 4
quarter special incentive contestŠAchieve Success and the rewards are high!

Our Core Objectives in PAH for 2010 will remain:

1. Continue to build Letairis as the ERA of Choice (surpass Tracleer in
market share)
* Drive clinically relevant differentiation within the ERA class

i. Focus on Efficacy, LFT, DDI, and simple
dosing messages
b. Improve branded persistency to keep appropriate patients
on therapy
c. Educate on improved access through integrated LEAP/
LabSync and reduced lab monitoring burden for prescribers and patients with
LabSync


1. Drive Letairis business through selected community physicians who
initiate oral treatment for PAH
* Increase penetration into community by supporting practices with
appropriate education and tools
* Continue to demonstrate the clinical benefits of Letairis in
appropriate patients


1. Reinforce the value of the endothelin pathway as first-line treatment
(in mono or combo therapy)

I look forward to seeing all of you in San Diego

Happy New Year!

Dave

 

Happy Presidents Day


Team-

Welcome to 2010!

First, let me take this opportunity to wish a very Happy New Year to all of
you and hope you thoroughly enjoyed the time off with friends and family as
I did.

At the upcoming National Meeting in San Diego later this month we will come
together to calibrate our individual and collective objectives, priorities
and tactical approaches that will define our success in 2010. We will also
take the opportunity to celebrate our successes in 2009 as President¹s Club
Winners, Director¹s Awards Winners, Quarterly Award Winners and Sprint to
the Finish Contest Winners will be recognized.

As you are all aware, this year there is a special incentive compensation
opportunity to strive for in the form of an unprecedented 4 quarter long
sales contest was rolled out last Fall providing each of you the opportunity
to add a whopping 50% payout on top of your standard incentive compensation
payout if you are able to achieve a cumulative IC attainment of 95% or
greater over the 4 quarter contest period (Q409 and Q1, Q2 and Q3
2010)Šsimply put, a quick start out of the gates over the next few weeks and
on the heels of the upcoming National Meeting is a great chance to
capitalize on the Q1 incentive program and position yourself well for the 4
quarter special incentive contestŠAchieve Success and the rewards are high!

Our Core Objectives in PAH for 2010 will remain:

1. Continue to build Letairis as the ERA of Choice (surpass Tracleer in
market share)
* Drive clinically relevant differentiation within the ERA class

i. Focus on Efficacy, LFT, DDI, and simple
dosing messages
b. Improve branded persistency to keep appropriate patients
on therapy
c. Educate on improved access through integrated LEAP/
LabSync and reduced lab monitoring burden for prescribers and patients with
LabSync


1. Drive Letairis business through selected community physicians who
initiate oral treatment for PAH
* Increase penetration into community by supporting practices with
appropriate education and tools
* Continue to demonstrate the clinical benefits of Letairis in
appropriate patients


1. Reinforce the value of the endothelin pathway as first-line treatment
(in mono or combo therapy)

I look forward to seeing all of you in San Diego

Happy New Year!

Dave

 

Is there a reason why some RE TARD continues to post this OLD NEWS posting? Go to work so that your group is finally PROFITABLE!!!

 

Its the same classic RE TARD that was threatened Dave got a piece he never could get!!

 

Off label is off label...

 

Spring has sprung... Now that all of the inappropriate goal is washed out and te decision was made that certain MDs do not count toward goal...this off label approach of DW's just might work... Rock on Puddy, rock on.

Team-

Welcome to 2010!

First, let me take this opportunity to wish a very Happy New Year to all of
you and hope you thoroughly enjoyed the time off with friends and family as
I did.

At the upcoming National Meeting in San Diego later this month we will come
together to calibrate our individual and collective objectives, priorities
and tactical approaches that will define our success in 2010. We will also
take the opportunity to celebrate our successes in 2009 as President¹s Club
Winners, Director¹s Awards Winners, Quarterly Award Winners and Sprint to
the Finish Contest Winners will be recognized.

As you are all aware, this year there is a special incentive compensation
opportunity to strive for in the form of an unprecedented 4 quarter long
sales contest was rolled out last Fall providing each of you the opportunity
to add a whopping 50% payout on top of your standard incentive compensation
payout if you are able to achieve a cumulative IC attainment of 95% or
greater over the 4 quarter contest period (Q409 and Q1, Q2 and Q3
2010)Šsimply put, a quick start out of the gates over the next few weeks and
on the heels of the upcoming National Meeting is a great chance to
capitalize on the Q1 incentive program and position yourself well for the 4
quarter special incentive contestŠAchieve Success and the rewards are high!

Our Core Objectives in PAH for 2010 will remain:

1. Continue to build Letairis as the ERA of Choice (surpass Tracleer in
market share)
* Drive clinically relevant differentiation within the ERA class

i. Focus on Efficacy, LFT, DDI, and simple
dosing messages
b. Improve branded persistency to keep appropriate patients
on therapy
c. Educate on improved access through integrated LEAP/
LabSync and reduced lab monitoring burden for prescribers and patients with
LabSync


1. Drive Letairis business through selected community physicians who
initiate oral treatment for PAH
* Increase penetration into community by supporting practices with
appropriate education and tools
* Continue to demonstrate the clinical benefits of Letairis in
appropriate patients


1. Reinforce the value of the endothelin pathway as first-line treatment
(in mono or combo therapy)

I look forward to seeing all of you in San Diego

Happy New Year!

Dave